Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation.

Notably, lower dosage (once a day treatment) caused numerical decreases in the expression levels of Vegfa , Kdr , Flt4 , and Nrp1 , but the effect did not reach statistical significance in any of these cases (Fig. 3 b–g).

also in 111,027 other papers